VolitionRx Limited — Third Quarter 2026 Earnings Summary

VolitionRx Limited reported third-quarter 2026 revenue of approximately $1.6 million, a 157% increase from the prior year, driven by deferred revenue recognition. The company narrowed its operating loss to $3.3 million and reduced its net loss to $3.8 million while strengthening its balance sheet with $2.4 million in cash and the full repayment of a $7.5 million convertible note. Strategic progress includes the launch of the DETECSEPS program for sepsis detection, active licensing discussions for its Capture-Seq technology targeting a combined market over $36 billion, and a pending reimbursement submission for its lung cancer test in France. Additionally, the CEO and board voluntarily reduced their compensation by 50% to align with the company's cost-reduction efforts and commitment to securing licensing agreements.